Urinary Retention Associated With Cariprazine: A Case Report
We report on a case of urinary retention associated with cariprazine. Possible mechanisms for this adverse effect are discussed. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - November 1, 2018 Category: Neurology Tags: Case Reports Source Type: research
Fludarabine-Induced Posterior Reversible Encephalopathy Syndrome in a Pediatric Patient With β-Thalassemia: Case Report and Literature Review
We present the case of a pediatric patient with β-thalassemia who develops a fludarabine-induced posterior reversible encephalopathy while he received an induction regimen to achieve an allogenic hematopoietic cell transplantation. The clinical presentation consists in altered mental state, headache, status epilepticus, visual disturbance, and hypertension. His treatment was carried out with the suspension of the medication and the control of hypertension and status epilepticus; the final outcome was positive without additional complications. There are published reports about fludarabine toxicity in the central nervous sy...
Source: Clinical Neuropharmacology - November 1, 2018 Category: Neurology Tags: Case Reports Source Type: research
A Case of Musical Hallucinations Related to Mirtazapine
We report a 91-year-old man whose MHs were causally related to the antidepressant mirtazapine. Although mirtazapine is generally well tolerated, it may rarely cause MHs or other psychotic symptoms. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - November 1, 2018 Category: Neurology Tags: Case Reports Source Type: research
Levetiracetam-Induced Seizure Aggravation in Patients With Focal Cortical Dysplasia
Conclusions
Our results suggest that LEV may possibly induce seizure exacerbation in a subset of patients with focal cortical dysplasia–related epilepsy, although large studies are needed to establish the relation. Underlying causes of epilepsy could impact the treatment choice because electroclinical semiology might be the “final common pathway” of different epileptogenic mechanisms in diverse etiologies. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - November 1, 2018 Category: Neurology Tags: Case Reports Source Type: research
Tandospirone-Induced Rhabdomyolysis
Conclusion
This case suggests that careless high dosing of partial 5-HT1A receptor agonists is harmful to at-risk patients, such as adolescent patients with poor mental condition. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - November 1, 2018 Category: Neurology Tags: Case Reports Source Type: research
Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson’s Disease Psychosis
Conclusion
The data from the trials suggest that nighttime sleep improved with administration of pimavanserin, a novel 5-HT2A receptor inverse agonist/antagonist. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - November 1, 2018 Category: Neurology Tags: Review Articles Source Type: research
Cerebral Microbleeds and the Safety of Anticoagulation in Ischemic Stroke Patients: A Systematic Review and Meta-Analysis
Conclusions
The presence of CMBs increases the risk of ICH during anticoagulant treatment (especially warfarin) in IS patients. Further studies with larger numbers of patients are needed to confirm our conclusions. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - November 1, 2018 Category: Neurology Tags: Review Articles Source Type: research
Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia
Background
Natalizumab is the first targeted humanized monoclonal antibody to be approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). Natalizumab appears to be more effective than current first-line disease-modifying therapies. In our study, we aimed to evaluate the outcome of Saudi patients with active RRMS treated with natalizumab and compare the results with other outcomes in the Gulf and international trials.
Methods
We conducted a retrospective single-center observational study involving 32 patients with RRMS at King Abdulaziz Medical City in Jeddah, Saudi Arabia. The inclusion criteria in...
Source: Clinical Neuropharmacology - November 1, 2018 Category: Neurology Tags: Original Article Source Type: research
Fluoxetine-Induced Sleep Bruxism Rapidly Treated With Once-Nightly Dosing of Buspirone in a 6-Year-Old Girl
We report the case of a 6-year-old girl who was successfully treated with once-nightly dosing of buspirone for fluoxetine-induced sleep bruxism, which was confirmed with clear on-off-on treatment sequence. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - September 1, 2018 Category: Neurology Tags: Case Reports Source Type: research
Tardive Myoclonic Dyskinesia Responsive to Sodium Oxybate
We report the case of a 64-year-old man with tardive dyskinesia characterized by severe uncontrolled dystonic and myoclonic jerks of the face, shoulders, and arm and forearm muscles, which improved with oral sodium oxybate. Our case suggests the possibility to test sodium oxybate in patients with severe, drug-resistant hyperkinetic syndromes, especially when they are known to improve with alcohol. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - September 1, 2018 Category: Neurology Tags: Case Reports Source Type: research
Fluoxetine-Induced Skin Picking and Compulsive Behaviors in a Preschool Girl
We present the case of a preschool girl with separation anxiety disorder who displayed skin-picking and compulsive-asking behaviors after fluoxetine therapy. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - September 1, 2018 Category: Neurology Tags: Case Reports Source Type: research
Efficacy and Safety of Atypical Antipsychotics in Bipolar Disorder With Comorbid Substance Dependence: A Systematic Review
Conclusions
According to our results, even though AAPs are widely used and efficacious in treating the clinical symptoms of BD, there are not enough data to suggest their adjunctive benefit on craving and substance consumption. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - September 1, 2018 Category: Neurology Tags: Review Article Source Type: research
Movement Disorders After Exposure to Antipsychotic Drugs in Patients With Depressive Disorders
Objectives
The aims of the study were to explore the frequency of movement disorders (MDs) in depressive patients exposed to antipsychotic drugs (APDs) and to compare it with nonexposed depressive patients and APDs-treated schizophrenic patients.
Methods
Four hundred fifty-two depressive patients not exposed to APDs (group A), 156 depressives exposed to APDs (group B), and 75 patients with schizophrenia on APDs (group C) were recruited. Presence of MDs was explored by the Simpson-Angus and UKU scales (Registration: NCT02409823).
Results
Movement disorders were observed in 5%, 9%, and 13% of patients in groups A to ...
Source: Clinical Neuropharmacology - September 1, 2018 Category: Neurology Tags: Original Articles Source Type: research
Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship
Objectives
We aimed to assess the potential relationship between intrasubject 9-tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray plasma profiles and clinical effects elicited by subacute dosing in chronically treated patients with multiple sclerosis (MS).
Methods
The study design was pilot, single center, open, and prospective. The patients were challenged with a morning test dose of 2 THC/CBD sprays at a 15-minute interval. Venous blood samples were collected before the first spray administration and every 30 minutes after the second spray, until 240 minutes postdosing. Patients rated their spasticity by t...
Source: Clinical Neuropharmacology - September 1, 2018 Category: Neurology Tags: Original Articles Source Type: research
Treatment of Myasthenia Gravis With High-Dose Cholinesterase Inhibitors and Calcineurin Inhibitors Caused Spontaneous Muscle Cramps in Patients
Conclusions
Our data suggested that treatment with a high dose of ChEI and CNI accelerated the probability of cramps and reduced the QOL in MG patients. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - September 1, 2018 Category: Neurology Tags: Original Articles Source Type: research
